Active Biotech AB Interim report January - June 2012
August 10, 2012 08:30 (CEST)- Laquinimod - application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M
during third quarter 2012
- a Phase III study will be initiated in the US - TASQ - milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target
for Phase III study
- overall survival data from Phase II study presented - ANYARA - Phase III trial continuing according to plan
- 57-57 - a clinical trial in systemic sclerosis/scleroderma in progress
- ISI - project proceeding as planned
- The organization has been adapted to the company's new direction
- Net sales: SEK 96.6 M (228.8)
- Operating loss: SEK 120.6 M (profit: 70.6)
- Loss after tax: SEK 123.5 M (profit: 77.7)
- Loss per share for the period: SEK 1.79 (earnings: 1.14)
For further information, please contact:
Tomas Leanderson
President and CEO
Tel: +46 (0)46 19 20 95
Hans Kolam
CFO
Tel: +46 (0)46 19 20 44
Active Biotech AB (Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
This report is also available at www.activebiotech.com Fax: +46 (0)46 19 11 00